In a Nutshell
DSIP is not FDA-approved, evidence does not establish that it improves sleep, and in July 2026 it was the one peptide of seven that FDA's advisory committee declined to recommend for compounding.
Delta sleep-inducing peptide (DSIP) — recently designated emideltide — is a nine-amino-acid peptide first identified in the 1970s in rabbits, named for its association with delta-wave (deep) sleep. It is marketed for sleep quality, stress recovery and nervous-system restoration.
In July 2026 an FDA advisory committee reviewed seven peptides for the 503A Bulks List. Six received favorable votes. DSIP was the one that did not — declined 6–7 with one abstention, for proposed indications of opioid withdrawal, chronic insomnia and narcolepsy 1.
That is worth knowing precisely because it is the vote nobody selling DSIP has an incentive to publicize. It also happened on a day when the committee was otherwise voting against FDA staff reviewers and in favor of the peptides in front of it — a committee inclined to approve declined this one.
What the Committee Actually Said
The committee members who voted against cited insufficient evidence and the availability of approved alternatives 1. FDA staff had stated there is "a lack of safety and efficacy data" supporting its use 1.
The second reason is the more interesting one. For insomnia specifically, there are treatments with genuine evidence behind them — cognitive behavioral therapy for insomnia (CBT-I) has the strongest evidence base of anything in the field and is recommended as first-line, alongside several approved pharmacological options. A committee weighing an unproven peptide against a well-evidenced alternative had a straightforward comparison to make.
Full detail on all seven votes is on our FDA peptide status page.
What DSIP Is
DSIP was isolated in the 1970s from the cerebral venous blood of rabbits during induced sleep, and named for the delta-wave activity it appeared to promote. It was first characterized in the 1970s and has been studied intermittently since.
Despite half a century of intermittent research, its physiological role remains poorly defined. It does not have a clearly established receptor, and reported effects across studies have been inconsistent. That combination is unusual — most peptides in this category are recent enough that thin evidence reflects insufficient time. DSIP has had fifty years, and the picture is still unclear.
Current FDA and Compounding Status
DSIP is not approved by FDA for any use.
It appears on FDA's list of bulk substances "nominated but withdrawn" — previously Category 2 2. The nominator later withdrew the nomination, but FDA elected to continue evaluating the free-base and acetate forms on its own initiative — which is why the substance still came before the committee. None of this is FDA clearance: removal from Category 2 does not by itself make a substance eligible for compounding.
Eligibility runs through one of three statutory routes under Section 503A — an applicable USP/NF monograph, being a component of an FDA-approved drug, or the 503A Bulks List — and every other 503A requirement still applies. For this substance FDA found no applicable USP/NF monograph and no FDA-approved drug containing it, so the 503A Bulks List is the only route identified in FDA's current review. The committee's vote did not add it to that list and changed no present authority to compound it.
FDA's stated concern: compounded emideltide "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization," with no safety-related information identified for the proposed route 2.
What the Evidence Actually Shows
Evidence tier: C.
| Claim commonly made | What the evidence supports |
|---|---|
| Induces deep / delta-wave sleep | The original observation. Human studies since have been small and inconsistent |
| Improves sleep quality | Not established in controlled trials; FDA cited a lack of efficacy data |
| Reduces stress | Not established |
| Helps opioid withdrawal | Considered and declined by the FDA advisory committee |
| Restores nervous system function | Not a defined clinical outcome; not supported |
Safety and What Is Unknown
- Safety data: FDA identified no safety-related information for the proposed route 2
- Long-term effects: unknown
- What FDA actually found: no clinical safety data for the proposed subcutaneous product. In small intravenous studies in people with withdrawal symptoms, reported events included transient headache, nausea and vertigo, and cases of hypotension — one described as progressive after a second intravenous injection. The underlying withdrawal state makes causal interpretation difficult
- A possible drug interaction: FDA identified a potential pharmacokinetic interaction with inhibitors of peptidyl dipeptidase A, citing captopril as an example
- Abuse potential: unresolved nonclinical questions about opioid-system effects
- Sedating medicines: no reliable human interaction profile exists for alcohol, benzodiazepines or opioids. Do not combine an unapproved sleep product with them without review by the clinician managing them
- Pregnancy and breastfeeding: no data; not appropriate
- Product risk: most DSIP in circulation is research-grade — see peptide sourcing and quality
Red Flags — Seek Care Now
- Symptoms of low blood pressure — dizziness on standing, faintness — particularly after a repeat dose
- Excessive sedation, confusion, or difficulty waking — particularly if combined with any other sedating substance
- Difficulty breathing, facial or throat swelling, widespread hives — call 911
- Fever, spreading redness or swelling at an injection site
On Dosing
This page does not provide dosing protocols. No validated subcutaneous dosing regimen has been established for opioid withdrawal, chronic insomnia or narcolepsy. Doses used in small intravenous studies do not create a treatment protocol for a marketed subcutaneous product.
What You Can Do About It — Sleep, Properly
Insomnia is one of the areas where the gap between marketed solutions and effective ones is widest, and the effective options are genuinely good.
- CBT-I (cognitive behavioral therapy for insomnia) — first-line, with the strongest evidence base of any insomnia treatment, and durable after treatment ends in a way medication is not
- Rule out sleep apnea — common, underdiagnosed, and it makes every other intervention fail
- Check for treatable drivers — thyroid dysfunction, iron deficiency, depression, anxiety, alcohol, and medication timing
- Hormonal change — in perimenopause and menopause, sleep disruption is frequently hormonally driven, and treating that directly works better than layering sedatives on top. See menopause insomnia and waking at 3 a.m.
Get Started with JumpstartMD
If sleep is what brought you here, it is worth saying plainly: an unapproved peptide that an FDA advisory committee has just declined is unlikely to be your best available option, and the alternatives are better than most people realize.
JumpstartMD was founded in 2007 by Stanford-trained physicians. Our programs are built around labs, hormones and body composition, delivered by licensed clinicians you see face-to-face — in person at 14 California locations or online across California — beginning with 60-biomarker lab screening and InBody® body composition scanning. Where sleep disruption is hormonally driven, particularly in perimenopause and menopause, treating the cause is a considerably more productive route than sedation. InBody scans are done in clinic; online members can book one at any of the 14 locations.
Can you get DSIP on prescription?
DSIP is not an FDA-approved drug, and in July 2026 an FDA advisory committee declined to recommend it for compounding eligibility.
If the symptom or goal that led you here has not been evaluated, our clinicians can assess the relevant causes and evidence-based options — that assessment does not assume another peptide is the answer. Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.
Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Share your details and a JumpstartMD team member will reach out when we open.
Related Articles
- Are Peptides Legal in the US? — all seven July 2026 votes
- Menopause Insomnia — hormonally driven sleep disruption
- Waking at 3 a.m.
- How to Tell If a Peptide Is Legitimate
- Peptide Therapy: What It Is and Who It's For
Frequently Asked Questions
What are the benefits of DSIP peptide?
DSIP is marketed for deep sleep, stress recovery and nervous-system restoration. These claims trace to its 1970s discovery in association with delta-wave sleep. Human studies since have been small and inconsistent, and in July 2026 an FDA advisory committee declined to recommend it for compounding, citing insufficient evidence and available approved alternatives.
Why did the FDA panel reject DSIP?
The committee voted 6–7 with one abstention against recommending it. Members cited insufficient evidence and the availability of approved alternatives; FDA staff had noted a lack of safety and efficacy data. Notably, the same committee voted in favor of the other six peptides it reviewed, often contrary to the conclusions presented by FDA staff reviewers.
How long does it take for DSIP to kick in?
There is no evidence-based answer. Small controlled intravenous studies did measure acute sleep effects — including a randomized, double-blind, placebo-controlled crossover in six people with chronic insomnia. They are far too small and inconsistent to establish a reliable onset or a clinically meaningful benefit, and they used a different route from the subcutaneous product FDA evaluated.
How does DSIP make you feel?
Blinded human studies do exist, but they are too small, too inconsistent and too route-specific to establish how anyone should expect DSIP to feel. Subjective sleep quality is also among the outcomes most susceptible to expectation.
What are the side effects of DSIP?
FDA found no clinical safety data for the proposed subcutaneous product. In small intravenous studies it identified transient headache, nausea and vertigo, and cases of hypotension including one progressive case after a repeat injection — though the withdrawal setting makes causation hard to read. FDA also flagged a possible interaction with peptidyl dipeptidase A inhibitors such as captopril, and unresolved questions about abuse potential.
Is DSIP legal?
It is not an FDA-approved drug, and unlike the other six peptides reviewed in July 2026, it did not receive a favorable advisory vote for compounding eligibility. Products sold online may be labeled "research use only" or "not for human use," but that disclaimer does not authorize human use or determine whether the sale complies with federal or state law.
References
- Regulatory Affairs Professionals Society, "FDA advisory committee backs two more peptides, rejects one for compounding list," Jul. 2026. [Online]. Available: https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html [Accessed: Jul. 25, 2026]. ↩
- U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [Accessed: Jul. 25, 2026]. ↩
- D. Riemann, C. A. Espie, E. Altena, E. S. Arnardottir, C. Baglioni, C. L. A. Bassetti, C. Bastien, N. Berzina, B. Bjorvatn, D. Dikeos, et al., "The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023," Journal of Sleep Research, vol. 32, no. 6, p. e14035, Dec. 2023, [Online]. Available: https://doi.org/10.1111/jsr.14035. PMID: 38016484. [Accessed: Jul. 25, 2026]. ↩
- G. A. Schoenenberger, M. Monnier, "Characterization of a delta-electroencephalogram (-sleep)-inducing peptide," Proceedings of the National Academy of Sciences of the United States of America, vol. 74, no. 3, pp. 1282-1286, Mar. 1977, [Online]. Available: https://doi.org/10.1073/pnas.74.3.1282. PMID: 265572. PMCID: PMC430668. [Accessed: Oct. 5, 2026]. ↩
- V. M. Kovalzon, T. V. Strekalova, "Delta sleep-inducing peptide (DSIP): a still unresolved riddle," Journal of Neurochemistry, vol. 97, no. 2, pp. 303-309, Apr. 2006, [Online]. Available: https://doi.org/10.1111/j.1471-4159.2006.03693.x. PMID: 16539679. [Accessed: Oct. 5, 2026]. ↩